Skip to main content
. 2026 Jan 9;20:2055. doi: 10.3332/ecancer.2026.2055

Table 2. Details of final histopathological examination report.

Parameters ULMS
(n = 44)
LGESS
(n = 25)
HGESS
(n = 9)
OTHERS
(n = 7)
Stage I 32 (37.6) 14 (16.5) 4 (4.7) 4 (4.7)
II 9 (10.6) 8 (9.4) 3 (3.5) 1 (1.2)
III 2 (2.4) 2 (2.4) 1 (1.2) 1 (1.2)
IV 1 (1.2) 1 (1.2) 1 (1.2) 1 (1.2)
Tumor size <5 cm 1 (1.2) 16 (18.8) 3 (3.5) 0 (0)
>5 cm 43 (50.6) 9 (10.6) 6 (7) 7 (8.2)
Tumor site Intramural 31 (36.5) 10 (11.8) 6 (7) 2 (2.4)
Subserosal 8 (9.4) 13 (15.3) 2 (2.4) 5 (5.9)
Submucosal 5 (5.9) 2 (2.4) 1 (1.2) 0 (0)
IHC ER+ PR− 0 (0) 5 (5.9) 1 (1.2) 0 (0)
ER− PR+ 0 (0) 1 (1.2) 1 (1.2) 0 (0)
Both+ 0 (0) 11 (12.9) 2 (2.4) 0 (0)
Both− 0 (0) 0 (0) 1 (1.2) 0 (0)
Not available 44 (51.8) 8 (9.4) 4 (4.7) 7 (8.2)
Other structures involvement Ovary 6 (7.1) 5 (5.9) 1 (1.2) 1 (1.2)
Lymph node 1 (1.2) 1 (1.2) 2 (2.4) 1 (1.2)

ER, estrogen receptor; HGESS, high grade endometrial stromal sarcoma; LGESS, low grade endometrial stromal sarcoma; PR, progesterone receptor